Aspira Women's Health appoints Sandra Milligan as President effective April 1, 2024

Aspira Women's Health Inc.

Dr. Sandra Milligan appointed President, reporting to CEO Nicole Sandford, effective April 1, 2024.
Base salary of $400,000; eligible for bonus up to 50% of base salary based on corporate goals.
Granted stock option for 30,000 shares, vesting 25% per year over four years.
Severance: 6 months salary and COBRA if terminated without cause after 12 months of employment.
Over 25 years healthcare experience; previously EVP R&D at Organon, roles at Amgen, Genentech, Merck.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandra Milligan

President

AWHL · Aspira Women's Health Inc.

Effective: 2024-04-01
Filed: March 21, 2024, 7:59 PM ET

On March 16, 2024, Aspira Women’s Health Inc. (the “Company”) expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President, effective as of April 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra Milligan was appointed as President at Aspira Women's Health Inc..

Action: appointed
Role: President

Exact text from the filing

On March 16, 2024, Aspira Women’s Health Inc. (the “Company”) expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President, effective as of April 1, 2024

View on SEC.gov

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.